In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
Subscribe To Our Newsletter & Stay Updated
